HRP20191489T1 - Kombinirani sastav - Google Patents

Kombinirani sastav Download PDF

Info

Publication number
HRP20191489T1
HRP20191489T1 HRP20191489T HRP20191489T1 HR P20191489 T1 HRP20191489 T1 HR P20191489T1 HR P20191489 T HRP20191489 T HR P20191489T HR P20191489 T1 HRP20191489 T1 HR P20191489T1
Authority
HR
Croatia
Prior art keywords
composition
combination
paracetamol
ibuprofen
use according
Prior art date
Application number
Other languages
English (en)
Croatian (hr)
Inventor
Hartley Campbell Atkinson
Original Assignee
Aft Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191489(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aft Pharmaceuticals Ltd filed Critical Aft Pharmaceuticals Ltd
Publication of HRP20191489T1 publication Critical patent/HRP20191489T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
HRP20191489 2010-11-04 2011-10-26 Kombinirani sastav HRP20191489T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ58901110 2010-11-04
PCT/NZ2011/000226 WO2012060719A1 (en) 2010-11-04 2011-10-26 A combination composition
EP11838295.1A EP2635269B1 (en) 2010-11-04 2011-10-26 A combination composition

Publications (1)

Publication Number Publication Date
HRP20191489T1 true HRP20191489T1 (hr) 2019-11-15

Family

ID=46024668

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20191489 HRP20191489T1 (hr) 2010-11-04 2011-10-26 Kombinirani sastav

Country Status (28)

Country Link
US (6) US20130225685A1 (https=)
EP (1) EP2635269B1 (https=)
JP (2) JP2013541583A (https=)
KR (1) KR101900520B1 (https=)
CN (2) CN103298464A (https=)
AU (1) AU2011324137B2 (https=)
BR (1) BR112013010829B8 (https=)
CA (1) CA2814057C (https=)
CL (1) CL2013001250A1 (https=)
CO (1) CO6771406A2 (https=)
CY (1) CY1123398T1 (https=)
DK (1) DK2635269T3 (https=)
ES (1) ES2742373T3 (https=)
HR (1) HRP20191489T1 (https=)
HU (1) HUE045442T2 (https=)
LT (1) LT2635269T (https=)
MX (2) MX2013005113A (https=)
MY (1) MY160572A (https=)
NZ (1) NZ609727A (https=)
PH (2) PH12013500689A1 (https=)
PL (1) PL2635269T3 (https=)
PT (1) PT2635269T (https=)
RS (1) RS59258B1 (https=)
RU (2) RU2707089C2 (https=)
SG (1) SG189319A1 (https=)
SI (1) SI2635269T1 (https=)
SM (1) SMT201900481T1 (https=)
WO (1) WO2012060719A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130225685A1 (en) 2010-11-04 2013-08-29 Aft Pharmaceuticals Limited Combination composition
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
WO2016008546A1 (en) 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen
KR20170066549A (ko) * 2014-10-06 2017-06-14 큠버랜드 파마슈티컬즈 인코포레이티드 통증 치료를 위한 이부프로펜과 아세트아미노펜의 공동 정맥 투여
WO2018192664A1 (en) 2017-04-20 2018-10-25 Hyloris Developments Sa METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF
CN114681324B (zh) * 2017-07-10 2024-05-03 盖尔凯普科技有限公司 双释放剂型胶囊及其制备方法、装置和系统
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
US11568752B2 (en) * 2020-01-28 2023-01-31 David Clark Company Incorporated Gateway retrieval alert device for aircraft pushback operations
WO2023281089A2 (en) 2021-07-08 2023-01-12 Krka, D.D., Novo Mesto Pharmaceutical composition comprising naproxen and paracetamol
IL324832A (en) 2023-06-02 2026-01-01 Ioulia Tseti Pharmaceutical composition comprising ibuprofen
GR1010809B (el) * 2023-09-13 2024-10-25 Ιουλια Τσετη Υδατικο διαλυμα ιβουπροφαινης παρακεταμολης για χρηση σε ενδοφλεβια χορηγηση
GR1010769B (el) * 2023-07-27 2024-09-18 Ιουλια Κλεωνος Τσετη Υδατικο διαλυμα ιβουπροφαινης για χρηση σε ενδοφλεβια χορηγηση

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020551A1 (en) * 1995-12-05 1997-06-12 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
DE60114249T2 (de) * 2001-11-02 2006-05-18 Cumberland Pharmaceuticals Inc., Nashville Pharmazeutische zusammensetzung mit 2-(4-isobutylphenyl) propionsäure
CN1758904A (zh) * 2003-03-21 2006-04-12 麦克内尔-Ppc股份有限公司 非甾体抗炎药物的给药方案
ATE543491T1 (de) * 2004-07-07 2012-02-15 Aft Pharmaceuticals Ltd Kombinationspräparat enthaltend ibuprofen und paracetamol
KR20060072839A (ko) * 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
US7934627B2 (en) * 2005-10-13 2011-05-03 Alcoa Inc. Apparatus and method for high pressure extrusion with molten aluminum
CA2666582C (en) * 2006-10-20 2014-09-09 Mcneil-Ppc, Inc. Acetaminophen / ibuprofen combinations
WO2008079818A2 (en) * 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Intravenous administration of water soluble analgesic formulations
US20090264530A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
US20110166234A1 (en) * 2008-10-14 2011-07-07 Atkinson Hartley Campbell Medicinal product and treatment
KR20140014350A (ko) * 2009-03-12 2014-02-06 큠버랜드 파마슈티컬즈 인코포레이티드 정맥 내 투여용 이부프로펜의 투여
SG186388A1 (en) * 2010-07-07 2013-01-30 Aft Pharmaceuticals Ltd A combination composition comprising ibuprofen and paracetamol
US20130225685A1 (en) 2010-11-04 2013-08-29 Aft Pharmaceuticals Limited Combination composition
KR20170066549A (ko) * 2014-10-06 2017-06-14 큠버랜드 파마슈티컬즈 인코포레이티드 통증 치료를 위한 이부프로펜과 아세트아미노펜의 공동 정맥 투여

Also Published As

Publication number Publication date
BR112013010829A2 (pt) 2016-08-16
US20190029982A1 (en) 2019-01-31
KR101900520B1 (ko) 2018-09-19
RU2015103107A (ru) 2015-06-20
SI2635269T1 (sl) 2019-10-30
US20250134839A1 (en) 2025-05-01
EP2635269A1 (en) 2013-09-11
CN107519159A (zh) 2017-12-29
US20160235695A1 (en) 2016-08-18
RU2015103107A3 (https=) 2018-08-20
CL2013001250A1 (es) 2013-08-30
BR112013010829B8 (pt) 2022-01-04
RU2707089C2 (ru) 2019-11-22
PT2635269T (pt) 2019-09-04
DK2635269T3 (da) 2019-08-26
CO6771406A2 (es) 2013-10-15
LT2635269T (lt) 2019-09-10
US11896567B2 (en) 2024-02-13
CY1123398T1 (el) 2021-10-29
NZ609727A (en) 2015-07-31
RU2013123646A (ru) 2014-12-10
SMT201900481T1 (it) 2019-11-13
HUE045442T2 (hu) 2019-12-30
MX367209B (es) 2019-07-22
JP2017132791A (ja) 2017-08-03
AU2011324137A1 (en) 2013-05-02
US12220392B2 (en) 2025-02-11
JP2013541583A (ja) 2013-11-14
MY160572A (en) 2017-03-15
PH12013500689A1 (en) 2013-05-27
WO2012060719A1 (en) 2012-05-10
AU2011324137B2 (en) 2015-05-07
MX2013005113A (es) 2013-06-03
RS59258B1 (sr) 2019-10-31
EP2635269B1 (en) 2019-05-22
JP6353577B2 (ja) 2018-07-04
BR112013010829B1 (pt) 2021-12-21
PL2635269T3 (pl) 2019-11-29
US20230000805A1 (en) 2023-01-05
CN103298464A (zh) 2013-09-11
SG189319A1 (en) 2013-05-31
KR20140025314A (ko) 2014-03-04
US11446266B2 (en) 2022-09-20
US20130225685A1 (en) 2013-08-29
ES2742373T3 (es) 2020-02-14
CA2814057C (en) 2022-02-01
US20240207210A1 (en) 2024-06-27
PH12021550804A1 (en) 2022-02-14
CA2814057A1 (en) 2012-05-10
EP2635269A4 (en) 2014-09-17

Similar Documents

Publication Publication Date Title
HRP20191489T1 (hr) Kombinirani sastav
CR20150232A (es) Imidazo [1,2-a] piridincarboxamidas aminosustituidas y su uso
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
WO2015038939A3 (en) Modulators of complement factor b
MX355294B (es) Artículos para el cuidado personal que tienen composiciones para el cuidado personal que tienen múltiples zonas amoldables.
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
CL2013003455A1 (es) Uso de compuestos inhibidores de sglt-2 derivados de benceno, sustituidos por glucopiranosilo para prevenir, desacelerar la progresion, retrasar o tratar un trastorno metabolico en un pacientes con un agente neuroleptico; uso de la combinacion del inhibidor de sglt2 con un neuroleptico; y composicion farmaceutica de la combinacion.
UY35693A (es) Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso
UY33984A (es) Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas
BR112015015864A2 (pt) composição farmacêutica, método de preparação de uma composição farmacêutica, método de tratamento de um indivíduo com uma condição de dor severa, e, uso de uma composição farmacêutica
BR112014011067A2 (pt) proteção absorvente descartável
GT201600002A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
MX390159B (es) Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada.
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
CL2014003081A1 (es) Una composicion farmaceutica topica que comprende, en base al peso total de la composicion, 1,5-5 % en peso de terbinafina, 15-35 % en peso de urea y mas que 25 % en peso de agua; y su uso para el tratamiento topico de una infeccion fungica, preferiblemente onicomicosis.
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
CO6551731A2 (es) Composiciòn de combinaciòn que comprende como ingrediente activo l- carnitina o propionil l- carnitina, para la prevenciòn o tratamiento de insuficienca venosa crònica
WO2014182789A3 (en) Radiomitigating pharmaceutical formulations
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas
MY164112A (en) A combination composition comprising ibuprofen and paracetamol
CL2012003065A1 (es) Combinación farmacéutica que comprende ibuprofeno y l-arginina en una proporción en peso de ibuprofeno/l-arginina entre 1.6 y 5.6, con excepción del valor 1.97; composición farmacéutica sólida que contiene a dicha combinación; y su uso en el tratamiento del dolor, inflamación y/o fiebre.
WO2015004634A3 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
BR112016006485A2 (pt) composições de liberação pulsátil revestidas por compressão
BR112015019387A2 (pt) alimentação mineral - através de formulação
CL2014002857A1 (es) Uso de 18-metil-15beta,16beta-metilen-19-nor-20-espirox-4-en-3-onas de formula (1) en el tratamiento de trastornos con sangrado uterino y hemorragias; sistema intrauterino que comprende 18-metil-15beta,16beta-metilen-19-nor-20-espirox-4-en-3-onas de formula (1).